Health Canada Approves Expansion of Mydecine's Cultivation
Increased cultivation capacity will enhance the Company’s ability to produce pharmaceutical grade psilocybin at scale...
Stay updated with breaking news from Rob Roscow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Increased cultivation capacity will enhance the Company’s ability to produce pharmaceutical grade psilocybin at scale...
Mydecine Innovations Group (OTC:MYCOF), a Denver-based psychedelics research company, announced its four lead novel drug candidates on Wednesday. The company plans to present the candidates at Pre-Investigational New Drug meetings with the FDA and Health Canada, a necessary step in obtaining approval for drug development and clinical trials. “We are essentially taking the value that is currently present in natural molecules, such as the psilocybin molecule in MYCO-001, and adding in patentable safety features,” said Rob Roscow, chief science officer and co-founder of Mydecine. The candida...
Psychedelic Stocks Poised to Resume the Upward Trend News Provided By Share This Article Fears of inflation and higher interest rates roiled the market for growth stocks, but the long-term prospects for psychedelic medicine remains bullish /EIN News/ -- ATLANTA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Fears of inflation and higher interest rates sent the NASDAQ Composite and Russell 2000 lower the past few weeks as many investors ran for cover. Almost as if on command, the same market pundits who were bullish prior to the correction suddenly voiced public concern about the valuations on psychedel...
Pipeline *NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES DENVER, Feb. 24, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced an exclusive partnership with Applied Pharmaceutical Innovation (API) at the University of Alberta, as well as expanded capabilities that enables support of multiple dru...
To better understand the therapeutic potential of naturally-occuring psilocybin, biotech and life sciences company Mydecine Innovations Group is taking steps to produce larger quantities of these molecules for research purposes. As part of this effort, Mydecine recently announced that it had completed the first harvest and commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. We spoke with Mydecineâs chief scientific officer and co-founder, Rob Roscow, to find out more. Ruairi Mackenzie (RM): Has the export of this harvest been a straightforward process? Ro...